One of the quieter problems in treating Crohn's disease is what to do when a drug that was working stops working. Patients on the anti-interleukin antibody ustekinumab often respond well at first and then experience what clinicians call a secondary loss of response — the disease creeps back after months of control. The intuitive move is to give more drug, more often, and in real-world practice physicians routinely escalate ustekinumab from a maintenance injection every eight weeks to one every four weeks. But intuition is not evidence, and the Phase 3 REScUE trial (NCT04245215) was built to test whether that dose-doubling actually helps. The registry record with full results is now public, and it is a useful corrective.
What makes this trial distinctive is its sponsorship. REScUE was run by the Belgian Inflammatory Bowel Disease Research and Development (BIRD) organization, an academic group, with Janssen as a collaborator rather than the lead. Investigator-initiated trials like this one tend to ask the questions that matter to practicing clinicians — does the common real-world maneuver work? — rather than the questions that support a label expansion, and they are correspondingly valuable as independent evidence.
It helps to understand what ustekinumab is and why it loses its grip. The drug is a monoclonal antibody that blocks the p40 subunit shared by interleukin-12 and interleukin-23, two cytokines that drive the inflammatory cascade in Crohn's disease. Loss of response over time can have several causes — the body may form anti-drug antibodies that clear the medication, drug levels may simply drift too low to suppress the inflammation, or the disease may shift toward inflammatory pathways the drug does not cover. Dose escalation is the bet that the problem is pharmacokinetic — that there is simply not enough drug on board — which is exactly the hypothesis REScUE was designed to interrogate.
The design and its clever wrinkle
The trial enrolled 108 adults with Crohn's disease who had demonstrated a secondary loss of response to ustekinumab. It was randomized, double-blind, and placebo-controlled in its masking. Every participant first received an intravenous re-induction dose of ustekinumab at roughly 6 mg/kg — essentially a reset, re-establishing higher drug levels. They were then randomized to one of two maintenance schedules for 48 weeks: 90 mg subcutaneously every eight weeks (the standard interval) or 90 mg every four weeks (the escalated interval). To keep the trial blinded, the every-eight-week group received placebo injections in the off weeks so that both arms received the same number of injections. That design choice is what makes the comparison clean: the only variable being tested is dosing frequency, because both groups got the intravenous re-induction.
What the evidence shows
The primary endpoint was demanding and clinically meaningful: the proportion of patients in steroid-free clinical remission with a fecal calprotectin below 250 micrograms per gram at week 48. Steroid-free matters because corticosteroids can mask disease activity; the calprotectin threshold adds an objective biomarker of gut inflammation on top of the symptomatic remission, so the bar requires both that the patient feels well and that the biology agrees.
At week 48, the every-four-week (escalated) arm had 8 of 54 patients meeting that combined endpoint, while the every-eight-week (standard) arm had 10 of 54. Read that carefully: the more intensive dosing schedule did not outperform the standard one on the primary outcome — if anything the standard arm numerically edged ahead, though with these small numbers the two are statistically indistinguishable. The endoscopic secondary endpoints tell a compatible story. Endoscopic remission at week 48 was reached by 15 of 54 in the every-four-week arm and 8 of 54 in the every-eight-week arm, while complete endoscopic remission was 4 versus 3 — small differences in both directions that do not establish a clear advantage for escalation.
How to interpret a result like this
The honest reading is that, once patients received an intravenous re-induction, doubling the maintenance frequency to every four weeks did not deliver a clear benefit over standard every-eight-week dosing in this trial. That is a genuinely useful clinical finding, and arguably more useful than a flashy positive result, because it questions an expensive and burdensome practice that many patients undergo by default. The re-induction itself — the reset both arms received — may be doing much of the work that clinicians attribute to ongoing frequent dosing. The serious-adverse-event counts were similar between arms, with 9 of 54 in the every-four-week group and 7 of 54 in the every-eight-week group, offering no safety argument for the more intensive schedule either.
The caveats matter and the trial does not hide them. With 108 patients split across two arms, REScUE is modestly sized, and small numbers limit its power to detect a real-but-small advantage. A combined symptomatic-plus-biomarker remission endpoint is a high bar that few patients in either arm cleared, which reflects how hard the loss-of-response population is to treat in the first place. None of that undermines the central message: the trial found no clear payoff for routine dose escalation once re-induction was given.
Why this trial matters
REScUE is exactly the kind of independent, question-driven study the evidence base needs — it tests a widely used real-world practice head-to-head rather than against placebo, and it reports a result that complicates the easy assumption that more drug is better. For clinicians weighing whether to escalate a Crohn's patient who has lost response to ustekinumab, the registry offers actual randomized data to consult instead of habit. The complete week-48 remission and endoscopic tables, along with the adverse-event listings, are posted on the ClinicalTrials.gov study page.